A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction

Abstract

Objective: To evaluate the clinical efficacy of a combined regimen of follicle stimulating hormone (FSH) and low dose human menopausal gonadotropin (hMG) following GnRH agonist ultralong protocol in controlled ovarian hyperstimulation (COH) for in vitro fertilization and embryo transfer (IVF-ET). Study design: IVF-ET was performed on 45 patients who had uterine or peritoneal factors, such as moderate to severe endometriosis, adenomyosis, or uterine myoma. The patients were randomized into two groups after the administration of long-acting GnRH agonist 2–4 times within a 4-week interval; highly purified FSH (FSH-HP) and hMG (Group A, n=26), FSH-HP only (Group B, n=19). hMG was administered at a fixed-dose of 75 IU per day and the dose of FSH-HP was adjusted according to the patient’s individual response. The results of COH and IVF-ET were assessed and compared between the two groups. Results: Serum estradiol (E 2) level on hCG day was significantly higher in Group A (1418.2±920.2 pg/ml, mean±S.D.) than in Group B (678.4±457.8 pg/ml) ( P<0.05). The clinical pregnancy rate and implantation rate tended to be higher in Group A than in Group B; 23.1% (6/26) versus 10.5% (2/19), 11.0% (9/82) versus 4.6% (3/65). Conclusion: In COH for IVF-ET using GnRH agonist ultralong protocol, the combined treatment of FSH-HP and low dose hMG showed a higher serum E 2 level when compared with treatment with FSH-HP alone.